Published in Curr Med Chem on January 01, 2010
High-fat diet-induced insulin resistance does not increase plasma anandamide levels or potentiate anandamide insulinotropic effect in isolated canine islets. PLoS One (2015) 1.41
Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol (2011) 1.05
Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists. J Med Chem (2012) 0.89
Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation. J Proteome Res (2011) 0.88
Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica (2011) 0.88
Cannabinoid modulation of neuroinflammatory disorders. Curr Neuropharmacol (2012) 0.80
Retracted Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment. J Biol Chem (2010) 0.79
Pyrazole antagonists of the CB1 receptor with reduced brain penetration. Bioorg Med Chem (2016) 0.78
Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner. Arthritis Res Ther (2015) 0.77
CB1 Receptors Signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology (2017) 0.75
Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands. ACS Med Chem Lett (2017) 0.75
Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer. Oncogene (2015) 0.75
Membrane-mediated action of the endocannabinoid anandamide on membrane proteins: implications for understanding the receptor-independent mechanism. Sci Rep (2017) 0.75
Cannabinoids Activate Monoaminergic Signaling to Modulate Key C. elegans Behaviors. J Neurosci (2017) 0.75
Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature (2007) 14.06
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Structure of a beta1-adrenergic G-protein-coupled receptor. Nature (2008) 11.97
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 7.78
The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol (2004) 7.38
Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol (2004) 6.80
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 6.55
Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (1996) 6.50
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 6.12
Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 5.70
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 5.30
Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther (1997) 5.20
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
A second endogenous cannabinoid that modulates long-term potentiation. Nature (1997) 4.79
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 4.22
Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 4.15
Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci U S A (2002) 4.12
Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron (2001) 3.98
Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov (2008) 3.93
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther (1998) 3.20
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 2.95
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med (2008) 2.60
Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A (2001) 2.58
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience (1997) 2.56
Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science (2002) 2.50
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A (2008) 2.42
Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A (1997) 2.25
G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J (1997) 2.25
Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J (1991) 2.23
Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun (2007) 2.18
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci (1998) 2.18
The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res (2009) 2.11
Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci (2000) 2.05
Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci (2003) 2.04
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci (1995) 1.94
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A (1996) 1.84
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci U S A (2009) 1.77
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol (1996) 1.75
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol (2007) 1.74
3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem (1999) 1.73
Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A (2007) 1.70
Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res (1999) 1.68
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther (1999) 1.67
Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry (1996) 1.66
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem (1996) 1.60
Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem (1999) 1.57
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med (2005) 1.56
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J (2000) 1.55
Cannabinoid-receptor expression in human leukocytes. Eur J Biochem (1993) 1.53
Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem (2000) 1.49
Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology (2005) 1.47
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem (1999) 1.44
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem (1993) 1.44
An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 1.43
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther (2002) 1.43
Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem (1997) 1.42
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett (2008) 1.36
A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol (1996) 1.35
Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (1998) 1.33
2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem (2008) 1.33
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol (2007) 1.32
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther (2001) 1.31
Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood (2002) 1.29
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol (2002) 1.28
GPCR structure-based virtual screening approach for CB2 antagonist search. J Chem Inf Model (2007) 1.28
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem (2004) 1.26
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
FRET-based monitoring of conformational change of the beta2 adrenergic receptor in living cells. Biochem Biophys Res Commun (2006) 1.23
Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol Pharmacol (2009) 1.23
The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther (1999) 1.23
3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins (2003) 1.22
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol (2008) 1.22
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther (1998) 1.20
Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur J Pharmacol (2003) 1.20
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem (1996) 1.19
On the conformational, physical properties and functions of polyunsaturated acyl chains. Biochim Biophys Acta (1991) 1.18
Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol (2008) 1.18